Plasma total @entity1255 levels in subjects with XXXX .

@entity1501 @entity6 @entity1255 @entity2690 @entity3190 @entity453 @entity3562 @entity413
OBJECTIVES: @entity3562 as well as @entity2690 resistance are considered to be risk factors for the development of @entity453 . This study was aimed at determining whether any relationship between plasma @entity2690 and @entity413 levels and total plasma @entity1255 (tHcy) concentrations exists in a population based survey performed 10 years apart. DESIGN AND SETTING: A cross-sectional study was undertaken during the years 1986-87 to examine risk factors for @entity6 and for @entity453 ( @entity453 ) in the Jewish population of Jerusalem. Ten years later two groups of individuals were invited for re-examination. SUBJECTS: Two groups of individuals were examined: the first one consisted of nondiabetic subjects (n = 86), who had @entity3190 10 years previously (at the first visit), the second group consisted of normoinsulinemic nondiabetic individuals (n = 265) who had initially normal @entity413 and @entity2690 levels. MAIN OUTCOME MEASURES: Metabolic, biochemical and anthropomorphic features were determined. Fasting and post load @entity413 , as well as @entity2690 concentrations on fasting and 2 h post @entity413 load were measured at the first and second visits. Plasma tHcy and @entity1501 were determined only at the second visit. RESULTS: The results demonstrated a significant negative correlation between plasma tHcy levels and @entity2690 levels at the second visit. No difference was found in @entity1501 levels between these two groups. CONCLUSIONS: In general, @entity3190 and @entity3562 are both related to an increased incidence of @entity453 . In our population most of the subjects examined had tHcy levels within the normal range and only a few demonstrated very high levels. However, negative association between @entity2690 levels and tHcy concentrations was found. Possible explanations for this finding are discussed.
